PLYMOUTH, Minn.--(BUSINESS WIRE)--Rotation Medical Inc., a medical device company focused on developing new technologies to treat rotator cuff disease, today announced results of a study published online in the Journal of Shoulder and Elbow Surgery that shows the company’s Bioinductive Implant consistently heals rotator cuff tears and mitigates tear progression. The Rotation Medical Bioinductive Implant is part of the company’s novel rotator cuff system for rotator cuff repair and a new alternative to traditional surgical repair.
“Partial thickness rotator cuff tears do not heal spontaneously and have a high propensity to increase in size and/or develop into full-thickness lesions,” said Theodore F. Schlegel, MD, lead investigator of the study and orthopedic surgeon at Steadman Hawkins Clinic Denver. “This study shows that the Bioinductive Implant not only repairs the tear and increases tendon thickness, but it also prevents tear progression. In addition, because the native tendon footprint remains intact around the location of the defect, the Bioinductive Implant may accelerate rehabilitation and recovery as compared with more conservative postoperative management when partial thickness lesions are taken down and repaired as full thickness tears.”
The study enrolled 33 patients with chronic, degenerative, intermediate- (n=12) to high-grade (n=21) partial-thickness tears (11 articular, 10 bursal, four intra-substance, eight hybrid) of the supraspinatus tendon. Clinical outcomes were assessed using American Shoulder and Elbow Surgeons (ASES) and Constant-Murley scores preoperatively and at three and 12 months postoperatively. Magnetic resonance imaging (MRI) was performed to assess postoperative tendon healing and thickness at the original tear site. One-year results of the multi-center study include:
- Clinical scores improved significantly (p<0.0001), and mean tendon thickness increased by 2.0 mm (p<0.0001); new tissue was indistinguishable from the underlying tendon.
- 94 percent of patients experienced complete healing or considerable reduction in defect size; consistent partial to complete fill-in of the original bursal, intrasubstance and articular partial-thickness tear defects were observed as early as three months postoperatively, with sustained efficacy through 12 months.
- 94 percent of patients either agreed or strongly agreed that they were satisfied with the results of their surgery.
- No tears progressed to full-thickness in patients who followed the postoperative rehabilitation protocol.
- No serious adverse events related to the implant were reported.
“In addition to further demonstrating that our Bioinductive Implant increases tendon thickness and prevents re-tears, we are pleased that the majority of patients in this study said they were satisfied with the results of their rotator cuff surgeries,” said Martha Shadan, president and CEO of Rotation Medical. “As health systems transition to value-based care, data like these are becoming increasingly necessary to demonstrate the effectiveness of medical devices on indicators such as patient satisfaction, in addition to key health economic drivers that we are measuring in our REBUILD Registry Study.”
The study, “Radiologic and clinical evaluation of a bioabsorbable collagen implant to treat partial-thickness tears: a prospective multi-center study,” adds to the growing body of literature supporting the use of the Rotation Medical Bioinductive Implant as a novel treatment for rotator cuff injury. Additional publications and information about the Rotation Medical rotator cuff system are available on the company’s website.
About Rotator Cuff Tears
Rotator cuff damage is the most
common source of shoulder pain, affecting more than 4 million people
annually in the U.S. Traditional approaches to treating degenerate or
torn rotator cuffs often do not address the poor quality of the
underlying tendon tissue, and a significant number of these tendons,
after standard treatment, either degenerate further and/or re-tear.
About the Rotation Medical Bioinductive Implant
Cleared by
the U.S. Food and Drug Administration in March 2014, the Rotation
Medical Bioinductive Implant is designed to address both the
biomechanics and biology required to heal a rotator cuff tendon tear by
inducing new tissue growth at the site of implantation, resulting in
increased tendon thickness and healing of tendon defects with new tissue
growth. The collagen-based implant is about the size of a postage stamp
and it is part of the Rotation Medical rotator cuff system, which also
includes disposable instruments that allow the arthroscopic procedure to
be performed easily and quickly. For important safety information, visit http://rotationmedical.com/our-solution/risks/.
About Rotation Medical
Rotation Medical Inc. was founded in
2009 and is committed to improving the treatment of rotator cuff disease
with the Rotation Medical rotator cuff system, a breakthrough technology
that has the potential to prevent rotator cuff disease progression and
reduce re-tears by inducing the growth of new tendinous tissue. The
company is privately held and funded by New Enterprise Associates (NEA),
Life Sciences Partners (LSP) and Pappas Ventures. For more information,
visit http://www.rotationmedical.com/.
